Study suggests that METTL3-mediated m6A methylation regulates diabetes-induced pericyte dysfunction, which could be a potential therapeutical target for diabetes-induced retinal vascular complication treatment (Suo et al., 2022). Here, METTL3 is linked to diabetes mellitus.